LRRK2 and Parkinson disease: MPTP administration increases LRRK2 transcript levels together with other PD-related proteins such as Parkin, PINK1, MUL1, and USP30 in both non-transgenic rodents and rhesus monkeys [147,148] and, thereby, could further contribute to the neurotoxicity in LRRK2 mutant models.